{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-048502","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.287578+00:00","generated_at":"2026-05-21T10:29:09.411088+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway","bullets":["Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.","Revenue $13.1M, flat YoY; includes $2.1M from Emrosi launch.","Gross margin improved to 64% from 54% YoY; R&D costs nil vs $7.9M.","Cash $21.1M at March 31, 2025 (vs $20.3M at Dec 31, 2024).","Emrosi commercial launch started April 7; Phase 3 results published in JAMA Dermatology."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-048502","json":"https://secwatch.observer/filing/0001104659-25-048502.json","markdown":"https://secwatch.observer/filing/0001104659-25-048502.md","text":"https://secwatch.observer/filing/0001104659-25-048502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925048502/0001104659-25-048502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925048502/tm2514979d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:29:09.411088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}